Nexstim (NXTMH) H2 2024 earnings summary

Executive summary

• Net sales grew 20.5% year-over-year to EUR 8.7 million, with profitable growth in H2 and FY 2024 and all sales comparable.

• EBITDA turned positive for the first time at EUR 0.3 million for FY, excluding non-recurring license income.

• New strategy period for 2025–2028 launched, focusing on diagnostics, therapy, research, and clinic partnerships.

• Signed significant partnerships with Brainlab (including up to EUR 5.1 million equity investment) and Sinaptica Therapeutics for Alzheimer's research.

• Emphasis on megatrends: aging population, healthcare technology, and cost pressures driving demand.

Financial highlights

• Full year 2024 net sales grew 20.5% to EUR 8.7 million; H2 net sales EUR 5.6 million (+17.2%).

• System sales up 19.5% to EUR 3.6 million in H2; recurring revenue increased 25% to EUR 3.9 million, now 45% of total net sales.

• Gross margin for 2024: EUR 6.9 million (79.0%), up from EUR 5.6 million (77.9%).

• EBITDA positive at EUR 0.3 million; operating loss reduced by 56% to EUR -0.5 million.

• Cash flow from operating activities turned positive at EUR 1.9 million, up from EUR -2.3 million in 2023; cash balance at year-end EUR 3.9 million, up 166%.

Outlook and guidance

• Net sales expected to grow and operating result to improve in 2025, supported by expanded distributor network and Brainlab partnership.

• Focus on profitable growth, strategic partnerships (especially Brainlab), and technology leadership, including launch of NBS 6 diagnostic system in key markets for 2025, pending regulatory approvals.